Skip to content
  • Home
  • About
    • Team
      • Our Board
      • Management Team
      • Clinical Ambassadors
    • Corporate Governance
    • Our Name & Brandmark
  • Care Delivery
    • Pax Centre
    • Emerald Clinics
    • Maritime Health Clinic
  • Drug and Therapy Development
    • Psychedelic-Assisted Therapy
    • Ultra-Pure CBD Medicines
    • MDMA-inspired Medicines
    • Research & Data Programs
  • Investor Hub
    • Shareholder Communications
  • News
    • General News
    • Blogs
    • Publications
    • Investor Updates
    • In the Media
  • Contact
Menu
  • Home
  • About
    • Team
      • Our Board
      • Management Team
      • Clinical Ambassadors
    • Corporate Governance
    • Our Name & Brandmark
  • Care Delivery
    • Pax Centre
    • Emerald Clinics
    • Maritime Health Clinic
  • Drug and Therapy Development
    • Psychedelic-Assisted Therapy
    • Ultra-Pure CBD Medicines
    • MDMA-inspired Medicines
    • Research & Data Programs
  • Investor Hub
    • Shareholder Communications
  • News
    • General News
    • Blogs
    • Publications
    • Investor Updates
    • In the Media
  • Contact

News

Back
  • Publications

Publication: Zelira/Emyria Observational Study Whitepaper

  • March 24, 2022

This observational White Paper published on the Zelira website analyses patient data generated by Emyria through their Emerald Clinics located in Western Australia (West Leederville), Victoria
(Balwyn), and New South Wales (Sydney, Alstonville, Goonellabah) using a bespoke data platform with ethically-sourced clinical evidence via their patients.

ZEL040-White-Paper_Hope_FA.pdf (zeliratx.com)

EMD-RX5 Recruitment Begins Blog: The Importance of an Over-The-Counter Treatment for Psychological Distress

For Investors

  • November 23, 2023

Proactive Interview

  • November 21, 2023

New Independent Non-Executive Chairman

Previous Next
Categories
  • Blogs
  • General News
  • In the Media
  • Investor Updates
    • Information
  • Publications
  • Uncategorised
Tags
  • anxiety
  • bioavailability
  • blog
  • CBD
  • clinical research
  • dr alistair vickery
  • drug development
  • EMD
  • EMD-RX5
  • emd-rx7
  • emyria
  • investor
  • mdma
  • mdma analogue program
  • medicinal cannabis
  • medicinal CBD treatments
  • national institutes for health
  • news
  • NINDS
  • opioid
  • over the counter
  • pain. preclinical
  • psychological conditions
  • psychological distress
  • screening results
  • ultra-pure CBD
  • webinar

Have Questions?

If you have any question, please feel free to get in touch with us.

Contact Us
DRUG & THERAPY DEVELOPMENT
  • Psychedelic-Assisted Therapy
  • Ultra-Pure CBD Medicines
  • MDMA-inspired Medicines
  • Research & Data Programs
  • Psychedelic-Assisted Therapy
  • Ultra-Pure CBD Medicines
  • MDMA-inspired Medicines
  • Research & Data Programs
CARE DELIVERY
  • Pax Centre
  • Emerald Clinics
  • Maritime Health Clinic
  • Pax Centre
  • Emerald Clinics
  • Maritime Health Clinic
FOR INVESTORS
  • Investor Hub
  • Corporate Governance
  • Investor Hub
  • Corporate Governance
RECENT TWEETS
© 2023 Emyria Limited

Website by Glide

  • Terms
  • Privacy Policy
  • Terms
  • Privacy Policy

Phone
08 6559 2800

Email
info@emyria.com

Linkedin Twitter Youtube